Loading company…
Irvine-based eye care therapeutics company founded in 2017 whose product XDEMVY treats Demodex blepharitis.
Tarsus Pharmaceuticals, Inc., founded in 2017 and based in California, US, is led by CEO Bobak Azamian and develops eye care therapeutics. Its product XDEMVY treats Demodex blepharitis, an eyelid disease caused by Demodex mite infestation. In February 2024 the company raised USD 100 million in a private placement, selling 2.81 million shares at USD 32 per share on the Nasdaq Global Select Market under the ticker TARS.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in